Asia Pacific Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity

You are here: 麻豆原创 Catalog Pharma & Healthcare Pharmaceutical Manufacturing Drug Delivery

Asia Pacific Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity

麻豆原创 Research Report Summary

Asia Pacific Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity report is published on December 29, 2020 and has 112 pages in it. This market research report provides information about Pharmaceutical Manufacturing, Drug Delivery, Pharma & Healthcare industry. It covers Asia Pacific market data and forecasts. It is priced starting at USD 2,800.00 for Single User License (PDF) which allows one person to use this report.

Please read the description and table of contents of this research report given below to check whether it meets your research requirements. If not, then please do not hesitate to contact us using "Report Enquiry" form given below. We can customize this research report or suggest a new fully customized market research report to meet your research goals and data requirements.

Asia Pacific Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity

Printer version

Send by email

Publication ID:听

GRM1220020

Publication Date:听

December 29, 2020

笔补驳别蝉:听

112

笔耻产濒颈蝉丑别谤:听

Grace 麻豆原创 Data

颁辞耻苍迟谤颈别蝉:听

Asia Pacific

USD 2,800.00

Pay By Invoice

If you wish to purchase this report using bank/wire transfer against an invoice, please fill your details using request invoice form given below.

Globally Trusted Brand

We help executives from firms听to Start-ups听with their market research needs thus听we can help you too.听

Secure Checkout

You can shop confidently as your online payments are processed using PCI DSS compliant secure payment gateways on our website.

Frequently Asked Questions

If you have any pre-sales听questions related to this report please let us know using the "Report Enquiry" form below. This will help us provide you听with answers听so that you can purchase with confidence. If you wish to read about frequently asked questions by our customers please visit our .

Tabs

Description

Asia Pacific pharmaceutical CRO market will grow by 9.6% annually with a total addressable market cap of $238.7 billion over 2020-2030 owing to the rising incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.
Highlighted with 33 tables and 44 figures, this 112-page report 鈥淎sia Pacific Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific pharmaceutical CRO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical CRO market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country.

Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� CRO for Pre-clinical Development
鈥� CRO for Phase I Trials
鈥� CRO for Phase II Trials
鈥� CRO for Phase III Trials
鈥� CRO for Phase IV Trials
鈥� Laboratory Services
鈥� Consulting Services
鈥� Data Management Services

Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Infectious Diseases
鈥� Oncology
鈥� Metabolic Disorders
鈥� Cardiovascular Disorders
鈥� Central Nervous System
鈥� Respiratory Disorders
鈥� Gastrointestinal Disorders
鈥� Other Therapeutic Applications

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Pharmaceutical & Biopharmaceutical Companies
鈥� Medical Device Companies
鈥� Academic Institutes

Geographically, the following national/local markets are fully investigated:
鈥� Japan
鈥� China
鈥� South Korea
鈥� Australia
鈥� India
鈥� Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific pharmaceutical CRO market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Asia Pacific Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table of Contents

Table of Contents
1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 7
1.2 Research Methodology 10
1.2.1 Overview of 麻豆原创 Research Methodology 10
1.2.2 麻豆原创 Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 13
1.2.6 麻豆原创 Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 麻豆原创 Overview and Dynamics 19
2.1 麻豆原创 Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the 麻豆原创 23
2.2 Major Growth Drivers 25
2.3 麻豆原创 Restraints and Challenges 30
2.4 Emerging Opportunities and 麻豆原创 Trends 33
2.5 Porter鈥檚 Fiver Forces Analysis 37
3 Segmentation of Asia Pacific 麻豆原创 by Service 41
3.1 麻豆原创 Overview by Service 41
3.2 CRO for Pre-clinical Development 43
3.3 CRO for Phase I Trials 44
3.4 CRO for Phase II Trials 45
3.5 CRO for Phase III Trials 46
3.6 CRO for Phase IV Trials 47
3.7 Laboratory Services 48
3.8 Consulting Services 49
3.9 Data Management Services 50
4 Segmentation of Asia Pacific 麻豆原创 by Therapeutic Application 51
4.1 麻豆原创 Overview by Therapeutic Application 51
4.2 Infectious Diseases 53
4.3 Oncology 54
4.4 Metabolic Disorders 55
4.5 Cardiovascular Disorders 56
4.6 Central Nervous System 57
4.7 Respiratory Disorders 58
4.8 Gastrointestinal Disorders 59
4.9 Other Therapeutic Applications 60
5 Segmentation of Asia Pacific 麻豆原创 by End User 61
5.1 麻豆原创 Overview by End User 61
5.2 Pharmaceutical & Biopharmaceutical Companies 63
5.3 Medical Device Companies 64
5.4 Academic Institutes 65
6 Asia-Pacific 麻豆原创 2019-2030 by Country 67
6.1 Overview of Asia-Pacific 麻豆原创 67
6.2 Japan 70
6.3 China 73
6.4 Australia 75
6.5 India 77
6.6 South Korea 80
6.7 Rest of APAC Region 82
7 Competitive Landscape 84
7.1 Overview of Key Vendors 84
7.2 New Product Launch, Partnership, Investment, and M&A 88
7.3 Company Profiles 89
Charles River Laboratories 89
CMIC Co. Ltd 91
Covance Inc. 92
Hangzhou Tigermed Consulting Co Ltd 93
ICON Plc 94
IQVIA Holdings Inc. 95
LSK Asia Pacific Pharma Service Co Ltd 96
Novotech Pty Ltd 97
PAREXEL International Corporation 98
Pharmaceutical Product Development LLC (PPD) 99
PRA Health Sciences Inc. 100
Quanticate Ltd 101
Samsung Bioepis Co. Ltd 102
SGS SA (SGS Life Sciences) 103
Syneos Health Inc. 104
WuXi AppTec Inc. 105
8 Investing in Asia Pacific 麻豆原创: Risk Assessment and Management 106
8.1 Risk Evaluation of Asia Pacific 麻豆原创 106
8.2 Critical Success Factors (CSFs) 109
Related Reports and Products 112

Companies Covered

Key Players (this may not be a complete list and extra companies can be added upon request):
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Enquiry / Request Invoice

Report Inquiry

Do you have more questions related to this market research report after going through the description and table of contents?

We are here to help. Please use the form given below to let us know your questions related to this report.

Kindly use your official email address and contact number to ensure speedy response.

First Name *

Last Name *

Company *

Email Address *

Phone (Including International Code) *

Report Title *

Do you need invoice for purchasing this report? *

Address 1

Address 2

City/Town

Postal/Zip Code

Country

License Type

Your Inquiry *

CAPTCHA

This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Pharmaceutical Manufacturing

Drug Delivery

Pharma & Healthcare

*Please note that the report cover image shown above is for representation purpose only. Actual report cover may vary.

听

Related 麻豆原创 Research Reports

Publication	Price
Global Thin Film Drugs 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031 The global Thin Film Drugs market size was valued at US$ 9429 million in 2024 and is forecast to a readjusted size of USD 17000 million by 2031 with a CAGR of 8.9% during review period. Thin-film drug delivery uses a dissolving film or oral drug strip to administer drugs via absorption in the mouth and/or via the small intestines. A film is prepared using hydrophilic polymers that rapidly dissolves on the tongue or buccal cavity, delivering the drug to the systemic circulation via dissolution when contact with liquid is made. Global Thin Film Drugs key players include GSK, LTS, J&J, Indivior, Pfizer, etc. Global top five manufacturers hold a share over 35%. Europe is the largest market, with a share about 40%, followed by Asia-Pacific, and North America, both have a share about 45 percent. In terms of product, Transdermal Film is the largest segment, with a share over 70%. And in terms of application, the largest application is Drugstores, followed by...Read more	USD 3,480.00
Global Plasma Protein Therapeutics 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031 The global Plasma Protein Therapeutics market size was valued at US$ 36350 million in 2024 and is forecast to a readjusted size of USD 59680 million by 2031 with a CAGR of 7.4% during review period. Plasma Protein Therapeutics is use blood products to treat disease.Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product. The plasma protein therapeutics market is driven by the increasing prevalence of rare and chronic diseases such as hemophilia, primary immunodeficiency, and autoimmune disorders, which require life-saving plasma-derived treatments. Advances in plasma fractionation techniques and the growing demand for immunoglobulins, albumin, and clotting factors are further fueling market growth. Additionally, improvements in diagnostic technologies have led to earlier detection and...Read more	USD 3,480.00
Global Vitamin D Testing 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031 The global Vitamin D Testing market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period. Vitamin D is vital for strong bones. It also has important, emerging roles in immune function and cancer prevention. Deficiencies at any stage of life can have devastating consequences. Similarly, vitamin D toxicity resulting from overmedication can cause serious hyperkalemia. Vitamin D consists of two bioequivalent forms: Vitamin D2: obtained from vegetable sources (dietary sources, supplements) Vitamin D3: derived from both endogenous (synthesized from cholesterol through sun exposure) and exogenous (animal diet) sources Vitamin D deficiency is more common than previously believed, especially among adolescents, women, and the elderly. For example, studies have shown that more than 50% of the institutionalized elderly and an equal proportion of women of any age undergoing treatment for...Read more	USD 3,480.00
Global Hemophilia Gene Therapy 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031 The global Hemophilia Gene Therapy market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period. Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males. Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc. This report is a detailed and comprehensive analysis for global Hemophilia Gene Therapy market. Both quantitative and...Read more	USD 3,480.00
Global Pharmaceutical Testing Services 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031 The global Pharmaceutical Testing Services market size was valued at US$ 4358 million in 2024 and is forecast to a readjusted size of USD 8568 million by 2031 with a CAGR of 10.3% during review period. Pharmaceutical Testing Service is often used to identify the chemical composition and molecular structure of each individual substance contained in a medication. This knowledge provides insight into a drug"s performance and safety considerations. Pharmaceutical testing can reveal a pharmaceutical"s solubility and can predict the medication"s ability to reach a specific target within the body. Testing may even reveal contamination in the manufacturing production process or highlight other, previously unknown risks with the formulation. Pharmaceutical Testing Services include raw materials testing, in-process and product release testing, finished pharmaceutical products testing and environmental samples, etc. It is mainly used in analytical testing,...Read more	USD 3,480.00

Clients Who Trust Us

Need tailor made market research solution? We can help you with that too.

Contact Us

About Us

At 麻豆原创 we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer鈥檚 needs, be it custom research or syndicated research reports.

Contact Us

麻豆原创 Research Reports, Inc
16192 Coastal Hwy
Lewes, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

Latest Blog Posts

Stay Connected

Disclaimer: 麻豆原创 has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom market research from our website 麻豆原创ResearchReports.com only.

If you are looking for a market research solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us.

麻豆原创